Research Progress of Immune Checkpoint Inhibitors in Melanoma

Abstract

Melanoma, also known as malignant melanoma, is a malignant tumor originating from melanocytes that is highly malignant, aggressive, and has a poor prognosis. Although melanoma accounts for about 10% of skin cancers, melanoma is the leading cause of death from skin cancers. Thus, it is essential to study the treatment of melanoma. Immunotherapy has produced durable clinical responses with long-term remissions in melanoma. In this article, we present a review of immune checkpoint inhibitors in melanoma treatment, and will introduce CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors.